ERBB2 and neoplasm: Other promising candidates for the alternative HER2 status assessment are molecular (multiplex ligation-dependent probe amplification) and liquid biopsy assays using circulating tumor cells, cell-free tumor DNA (ctDNA), and extracellular vesicles, which have been tested in IHC/ISH HER2-equivocal breast cancers.